<?xml version="1.0" encoding="UTF-8"?><oai_dc:dc xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">
  <dc:creator>GOICOECHEA CALVO, AROIA</dc:creator>
  <dc:creator>Escolar Castellón, Juan de Dios</dc:creator>
  <dc:title>FORAMEN OVAL PERMEABLE Y SU RELACIÓN ACTUAL CON LOS ACCIDENTES CEREBRO VASCULARES</dc:title>
  <dc:identifier>http://zaguan.unizar.es/record/47801</dc:identifier>
  <dc:publisher>Universidad de Zaragoza</dc:publisher>
  <dc:date>2015</dc:date>
  <dc:description>RESUMEN El foramen oval permeable (FOP) es una lesión cardíaca congénita presente en el 25% de la población adulta. Resulta de la falta de fusión del septum primum y secundum después del nacimiento, la mayoría se descubre de manera incidental y no tiene consecuencias clínicas. Sin embargo, recientemente su presencia se ha relacionado con múltiples entidades clínicas, como el ictus idiopático, de origen desconocido o criptogénico, la migraña, el síndrome de platipnea ortodesoxia y la enfermedad por descompresión. El ictus de origen desconocido o criptogénico representa hasta el 40% de todos los ictus isquémicos. Hay gran controversia respecto al papel del cierre percutáneo del foramen oval permeable en el ictus criptogénico. Recientemente se han publicado estudios aleatorizados, como son el CLOSURE, RESPECT y PC- trial, que no han conseguido demostrar que el cierre percutáneo se asocie a una reducción de ictus en comparación con el tratamiento médico con antiagregantes o anticoagulantes. Aun así, los últimos metanálisis de estos estudios, han demostrado que el cierre percutáneo del FOP podría ser beneficioso para determinados grupos de pacientes. En esta revisión bibliográfica se abordarán los mecanismos fisiopatogénicos involucrados en el ictus idiopático y el foramen oval permeable, los métodos diagnósticos, los beneficios existentes del cierre percutáneo del foramen oval permeable, junto a las indicaciones en los distintos grupos de riesgo, para poder prevenir los accidentes cerebrovasculares isquémicos relacionados con esta lesión cardíaca congénita ABSTRACT Patent foramen ovale (PFO) is a congenital heart defect present in 25% of the adult population. Results from the lack of fusión between septum primum and secundum after birth, most of them are discovered incidentally and have no clinical consequence. However, recently the presence of PFO has been associated with a range of clinical conditions such as cryptogenic stroke, migraine, platypnea- orthodeoxia syndrome, and decompression illness. Cryptogenic stroke, or the stroke of unknown origin, accounts for up to 40% of all ischemic strokes. There has been heated debate about the role of percutaneous closure of PFO in patients with cryptogenic stroke. Recently, randomized studies have been published such as CLOSURE, RESPECT, and PC-trial. None of these demonstrated that percutaneous closure was associated with a decreased incidence of stroke compared to medical treatment with antiplatelet agents or anticoagulants. Nevertheless, the last metaanalyses of these studies have shown that percutaneous closure of PFO could be beneficial for certain patient groups. In this review, were analyzed the pathophysiological mechanisms involved in idiopathic stroke and patent foramen ovale, the diagnostic methods, the benefits published of percutaneous closure, and the treatment indications established in the risk groups, in order to prevent ischemic stroke associated with this congenital heart defect.</dc:description>
  <dc:format>pdf</dc:format>
  <dc:language>spa</dc:language>
  <dc:type>info:eu-repo/semantics/bachelorThesis</dc:type>
  <dc:rights>by-nc-sa</dc:rights>
  <dc:rights>http://creativecommons.org/licenses/by-nc-sa/3.0/</dc:rights>
</oai_dc:dc>